Yang Liyuan,Gu Song,Wang Jing,et al.Research advances of m6A modification in hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2023,22(12):1130-1134.[doi:10.3760/cma.j.cn101785-202209040-007]
m6A修饰在肝母细胞瘤中的研究进展
- Title:
- Research advances of m6A modification in hepatoblastoma
- Keywords:
- Hepatoblastoma; Epigenomics; RNA; m6A Modification
- 摘要:
- 肝母细胞瘤(hepatoblastoma,HB)多见于2岁以下婴幼儿,是儿童罕见的恶性实体肿瘤,占儿童肝脏肿瘤的60%~85%,晚期病例预后差。核糖核酸(ribonucleic acid,RNA) N6-methyladenosine(m6A)修饰是真核生物RNA内普遍存在的表观遗传学修饰,广泛参与肿瘤的生物学过程。目前诸多研究发现m6A修饰在HB的发生、发展过程中起关键作用,选用合适检测手段深入研究m6A修饰的分子机制对于HB的诊断、预后评估以及靶向治疗具有重要意义。本文综述m6A修饰在HB中的研究进展,旨在阐明m6A修饰的分子机制及其作为HB生物学标志物和治疗靶点的潜在价值,探索HB的新型诊疗手段。
- Abstract:
- As a rare malignant solid tumor in children,hepatoblastoma (HB) is more common in infants aged 0 to 2 years,accounting for 60%-85% of pediatric liver tumors.The prognosis of advanced HB is rather poor.RNA m6A (N6-methyladenosine,m6A) is an ubiquitous epigenetic modification in eukaryotic RNA.It is extensively implicated in various biological processes of tumors.Many studies have demonstrated that m6A modification plays some vital roles in the occurrence and development of HB.Therefore selecting appropriate detection methods and elucidating the molecular mechanisms of m6A modification are significant for proper managements of HB.Summarizing the latest researches of m6A modification in HB,this review examined its potential value of biological markers or therapeutic targets for HB and provided rationales for new management tools for HB.
参考文献/References:
[1] Allan BJ,Parikh PP,Diaz S,et al.Predictors of survival and incidence of hepatoblastoma in the paediatric population[J].HPB (Oxford),2013,15(10):741-746.DOI:10.1111/hpb.12112.
[2] Nagae G,Yamamoto S,Fujita M,et al.Genetic and epigenetic basis of hepatoblastoma diversity[J].Nat Commun,2021,12(1):5423.DOI:10.1038/s41467-021-25430-9.
[3] Aguiar T,Teixeira A,Scliar MO,et al.Unraveling the genetic architecture of hepatoblastoma risk:birth defects and increased burden of germline damaging variants in gastrointestinal/renal cancer predisposition and DNA repair genes[J].Front Genet,2022,13:858396.DOI:10.3389/fgene.2022.858396.
[4] Cohen MM Jr.Beckwith-Wiedemann syndrome:historical,clinicopathological,and etiopathogenetic perspectives[J].Pediatr Dev Pathol,2005,8(3):287-304.DOI:10.1007/s10024-005-1154-9.
[5] Thomas D,Pritchard J,Davidson R,et al.Familial hepatoblastoma and APC gene mutations:renewed call for molecular research[J].Eur J Cancer,2003,39(15):2200-2204.DOI:10.1016/s0959-8049(03)00618-x.
[6] Boccaletto P,Stefaniak F,Ray A,et al.MODOMICS:a database of RNA modification pathways.2021 update[J].Nucleic Acids Res,2022,50(D1):D231-D235.DOI:10.1093/nar/gkab1083.
[7] Zhao BS,Roundtree IA,He C.Post-transcriptional gene regulation by mRNA modifications[J].Nat Rev Mol Cell Biol,2017,18(1):31-42.DOI:10.1038/nrm.2016.132.
[8] Desrosiers R,Friderici K,Rottman F.Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells[J].Proc Natl Acad Sci U S A,1974,71(10):3971-3975.DOI:10.1073/pnas.71.10.3971.
[9] Jia GF,Fu Y,Zhao X,et al.N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J].Nat Chem Biol,2011,7(12):885-887.DOI:10.1038/nchembio.687.
[10] Sun T,Wu RY,Ming L.The role of m6A RNA methylation in cancer[J].Biomed Pharmacother,2019,112:108613.DOI:10.1016/j.biopha.2019.108613.
[11] Zaccara S,Ries RJ,Jaffrey SR.Reading,writing and erasing mRNA methylation[J].Nat Rev Mol Cell Biol,2019,20(10):608-624.DOI:10.1038/s41580-019-0168-5.
[12] Meyer KD.DART-seq:an antibody-free method for global m6A detection[J].Nat Methods,2019,16(12):1275-1280.DOI:10.1038/s41592-019-0570-0.
[13] Tegowski M,Flamand MN,Meyer KD.scDART-seq reveals distinct m6A signatures and mRNA methylation heterogeneity in single cells[J].Mol Cell,2022,82(4):868-878.e10.DOI:10.1016/j.molcel.2021.12.038.
[14] Garalde DR,Snell EA,Jachimowicz D,et al.Highly parallel direct RNA sequencing on an array of nanopores[J].Nat Methods,2018,15(3):201-206.DOI:10.1038/nmeth.4577.
[15] Pratanwanich PN,Yao F,Chen Y,et al.Identification of differential RNA modifications from nanopore direct RNA sequencing with xPore[J].Nat Biotechnol,2021,39(11):1394-1402.DOI:10.1038/s41587-021-00949-w.
[16] K?rtel N,Rücklé C,Zhou Y,et al.Deep and accurate detection of m6A RNA modifications using miCLIP2 and m6Aboost machine learning[J].Nucleic Acids Res,2021,49(16):e92.DOI:10.1093/nar/gkab485.
[17] Perugorria MJ,Olaizola P,Labiano I,et al.Wnt-β-catenin signalling in liver development,health and disease[J].Nat Rev Gastroenterol Hepatol,2019,16(2):121-136.DOI:10.1038/s41575-018-0075-9.
[18] Crippa S,Ancey PB,Vazquez J,et al.Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma[J].EMBO Mol Med,2017,9(11):1589-1604.DOI:10.15252/emmm.201707814.
[19] López-Terrada D,Gunaratne PH,Adesina AM,et al.Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors[J].Hum Pathol,2009,40(6):783-794.DOI:10.1016/j.humpath.2008.07.022.
[20] Ashihara E,Takada T,Maekawa T.Targeting the canonical Wnt/β-catenin pathway in hematological malignancies[J].Cancer Sci,2015,106(6):665-671.DOI:10.1111/cas.12655.
[21] Liu L,Wang J,Sun GF,et al.m6A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma[J].Mol Cancer,2019,18(1):188.DOI:10.1186/s12943-019-1119-7.
[22] Yang WS,SriRamaratnam R,Welsch ME,et al.Regulation of ferroptotic cancer cell death by GPX4[J].Cell,2014,156(1/2):317-331.DOI:10.1016/j.cell.2013.12.010.
[23] Liu L,He JT,Sun GF,et al.The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma[J].Clin Transl Med,2022,12(5):e778.DOI:10.1002/ctm2.778.
[24] Ruan TY,He XT,Yu J,et al.MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo signaling and tumorigenesis in hepatocellular carcinoma[J].Oncol Lett,2016,11(4):2941-2945.DOI:10.3892/ol.2016.4312.
[25] von Frowein J,Pagel P,Kappler R,et al.MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma[J].Hepatology,2011,53(3):833-842.DOI:10.1002/hep.24125.
[26] 成英杰,单慈,石寒菡,等.MicroRNAs在肝母细胞瘤诊断、鉴别诊断及预后评估中的研究进展[J].临床小儿外科杂志,2019,18(8):660-663.DOI:10.3969/j.issn.1671-6353.2019.08.009. Cheng YJ,Shan C,Shi HH,et al.Research advances of microRNAs in the diagnosis,differential diagnosis and prognostic evaluation of hepatoblastoma[J].J Clin Ped Sur,2019,18(8):660-663.DOI:10.3969/j.issn.1671-6353.2019.08.009.
[27] Cui XC,Wang ZF,Li JH,et al.Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway[J].Cell Prolif,2020,53(3):e12768.DOI:10.1111/cpr.12768.
[28] Neviani P,Wise PM,Murtadha M,et al.Natural killer-derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms[J].Cancer Res,2019,79(6):1151-1164.DOI:10.1158/0008-5472.CAN-18-0779.
[29] Gou YL,Zhai FB,Zhang L,et al.RUNX3 regulates hepatocellular carcinoma cell metastasis via targeting miR-186/E-cadherin/EMT pathway[J].Oncotarget,2017,8(37):61475-61486.DOI:10.18632/oncotarget.18424.
[30] Li LL,Xie RR,Lu GR.Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma[J].Biosci Rep,2021,41(6):BSR20210760.DOI:10.1042/BSR20210760.
[31] Wang HX,Meng QK,Ma B.Characterization of the prognostic m6A-related lncRNA signature in gastric cancer[J].Front Oncol,2021,11:630260.DOI:10.3389/fonc.2021.630260.
[32] Tu ZW,Wu L,Wang P,et al.N6-methylandenosine-related lncRNAs are potential biomarkers for predicting the overall survival of lower-grade glioma patients[J].Front Cell Dev Biol,2020,8:642.DOI:10.3389/fcell.2020.00642.
[33] Zhang W,Liang F,Li QF,et al.LncRNA MIR205HG accelerates cell proliferation,migration and invasion in hepatoblastoma through the activation of MAPK signaling pathway and PI3K/AKT signaling pathway[J].Biol Direct,2022,17(1):2.DOI:10.1186/s13062-021-00309-3.
[34] Cui XC,Wang ZF,Liu LW,et al.The long non-coding RNA ZFAS1 sponges miR-193a-3p to modulate hepatoblastoma growth by targeting RALY via HGF/c-Met pathway[J].Front Cell Dev Biol,2019,7:271.DOI:10.3389/fcell.2019.00271.
[35] Chen HT,Duan F,Wang M,et al.Polymorphisms in METTL3 gene and hepatoblastoma risk in Chinese children:a seven-center case-control study[J].Gene,2021,800:145834.DOI:10.1016/j.gene.2021.145834.
[36] Chen HT,Chen Z,Wang M,et al.METTL14 gene polymorphisms influence hepatoblastoma predisposition in Chinese children:evidences from a seven-center case-control study[J].Gene,2022,809:146050.DOI:10.1016/j.gene.2021.146050.
[37] Zhuo ZJ,Hua RX,Chen Z,et al.WTAP gene variants confer hepatoblastoma susceptibility:a seven-center case-control study[J].Mol Ther Oncolytics,2020,18:118-125.DOI:10.1016/j.omto.2020.06.007.
[38] Chen HT,Li Y,Li L,et al.YTHDC1 gene polymorphisms and hepatoblastoma susceptibility in Chinese children:a seven-center case-control study[J].J Gene Med,2020,22(11):e3249.DOI:10.1002/jgm.3249.
[39] De Ioris M,Brugieres L,Zimmermann A,et al.Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis:the SIOPEL group experience[J].Eur J Cancer,2008,44(4):545-550.DOI:10.1016/j.ejca.2007.11.022.
[40] Ge LC,Zhang N,Chen ZJ,et al.Level of N6-methyladenosine in peripheral blood RNA:a novel predictive biomarker for gastric cancer[J].Clin Chem,2020,66(2):342-351.DOI:10.1093/clinchem/hvz004.
[41] Pei YQ,Lou XY,Li KX,et al.Peripheral blood leukocyte N6-methyladenosine is a noninvasive biomarker for non-small-cell lung carcinoma[J].Onco Targets Ther,2020,13:11913-11921.DOI:10.2147/OTT.S267344.
[42] Xiao H,Fan XB,Zhang R,et al.Upregulated N6-methyladenosine RNA in peripheral blood:potential diagnostic biomarker for breast cancer[J].Cancer Res Treat,2021,53(2):399-408.DOI:10.4143/crt.2020.870.
[43] Bedi RK,Huang DZ,Eberle SA,et al.Small-molecule inhibitors of METTL3,the major human epitranscriptomic writer[J].Chem Med Chem,2020,15(9):744-748.DOI:10.1002/cmdc.202000011.
[44] 俞星雨,顾松,李云洁,等.肝母细胞瘤Wnt/β-catenin信号通路研究进展[J].临床小儿外科杂志,2022,21(7):688-691.DOI:10.3760/cma.j.cn101785-202107049-018. Yu XY,Gu S,Li YJ,et al.Recent advance of Wnt/β-catenin signaling pathway in hepatoblastoma[J].J Clin Ped Sur,2022,21(7):688-691.DOI:10.3760/cma.j.cn101785-202107049-018.
相似文献/References:
[1]陈立才,李朋飞,黄一敏,等. 抗EpCAM单克隆抗体治疗肝母细胞瘤的动物实验研究[J].临床小儿外科杂志,2019,18(01):63.
Chen Licai,Li Pengfei,Huang Yimin,et al. Targeting therapy of antiEpCAM monoclonal antibody in hepatoblastoma animal model.[J].Journal of Clinical Pediatric Surgery,2019,18(12):63.
[2]成英杰,单慈,石寒菡,等.MicroRNAs在肝母细胞瘤诊断、鉴别诊断及预后评估中的研究进展[J].临床小儿外科杂志,2019,18(08):660.[doi:10.3969/j.issn.1671-6353.2019.08.009]
Cheng Yingjie,Shan Ci,Shi Hanhan,et al.Research advances of MicroRNAs in the diagnosis,differential diagnosis and prognostic evaluation of hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2019,18(12):660.[doi:10.3969/j.issn.1671-6353.2019.08.009]
[3]朱中贤,唐维兵.先天性肛门直肠畸形基础研究的进展与展望[J].临床小儿外科杂志,2022,21(11):1006.[doi:10.3760/cma.j.cn101785-202210017-002]
Zhu Zhongxian,Tang Weibing.Recent advances and future prospects of basic researches on congenital anorectal malformations[J].Journal of Clinical Pediatric Surgery,2022,21(12):1006.[doi:10.3760/cma.j.cn101785-202210017-002]
[4]王焕民.重视安全与历练,提高小儿肝胆肿瘤诊治水平[J].临床小儿外科杂志,2023,22(12):1101.[doi:10.3760/cma.j.cn101785-202310061-001]
Wang Huanmin.Further improving the diagnoses and treatments of pediatric hepatobiliary tumors[J].Journal of Clinical Pediatric Surgery,2023,22(12):1101.[doi:10.3760/cma.j.cn101785-202310061-001]
[5]唐湘莲,刘登辉,李勇.儿童肝母细胞瘤治疗难点与思考[J].临床小儿外科杂志,2023,22(12):1104.[doi:10.3760/cma.j.cn101785-202310045-002]
Tang Xianglian,Liu Denghui,Li Yong.Difficulties and reflections on proper treatments of hepatoblastoma in children[J].Journal of Clinical Pediatric Surgery,2023,22(12):1104.[doi:10.3760/cma.j.cn101785-202310045-002]
[6]林宇,王焕民,杨深,等.经导管动脉栓塞术治疗肝母细胞瘤破裂的初步探索[J].临床小儿外科杂志,2023,22(12):1109.[doi:10.3760/cma.j.cn101785-202310011-003]
Lin Yu,Wang Huanmin,Yang Shen,et al.Preliminary exploration of transcatheter arterial embolization for ruptured hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2023,22(12):1109.[doi:10.3760/cma.j.cn101785-202310011-003]
[7]徐晓钢,曾纪晓,罗媛圆,等.全球首例不阻断第一肝门的机器人肝切除术治疗儿童肝母细胞瘤[J].临床小儿外科杂志,2023,22(12):1114.[doi:10.3760/cma.j.cn101785-202307016-004]
Xu Xiaogang,Zeng Jixiao,Luo Yuanyuan,et al.Robotic hepatectomy in a 14-month-old child of hepatoblastoma without the first hepatic portal control:a first case report in the world[J].Journal of Clinical Pediatric Surgery,2023,22(12):1114.[doi:10.3760/cma.j.cn101785-202307016-004]
[8]刘百慧,解鲁璐,姚伟,等.联合肝脏离断和门静脉结扎二步肝切除术治疗儿童巨大肝母细胞瘤[J].临床小儿外科杂志,2023,22(12):1119.[doi:10.3760/cma.j.cn101785-202309028-005]
Liu Baihui,Xie Lulu,Yao Wei,et al.Application of associating liver partition and portal vein ligation during two-stage hepatectomy for massive hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2023,22(12):1119.[doi:10.3760/cma.j.cn101785-202309028-005]
[9]周恩卿,董瑞.黄连素在儿童胚胎源性肿瘤中的研究进展[J].临床小儿外科杂志,2023,22(12):1135.[doi:10.3760/cma.j.cn101785-202208042-008]
Zhou Enqing,Dong Rui.Research advances of berberine in pediatric embryonal tumors[J].Journal of Clinical Pediatric Surgery,2023,22(12):1135.[doi:10.3760/cma.j.cn101785-202208042-008]
备注/Memo
收稿日期:2022-9-24。
基金项目:国家自然科学基金(82072375; 82172357);2021年度国家临床重点专科建设项目[沪卫医(2021)99号]
通讯作者:顾松,Email:gusong@shsmu.edu.cn